Leukemia Program


The Penn Difference

Innovative Research...Advanced Medicine...Service Excellence

  • Nationally recognized experts with extensive experience in leukemia
  • Advanced diagnostic testing, treatments and technologies
  • Coordinated care throughout the experience
  • Support services and education programs
  • A reputation for sensitivity and responsiveness
  • Personalized attention
  • Innovative clinical trials
  • The backing of a major research program with immediate translation to patient care

What sets Penn’s Leukemia Program apart?

Penn’s program is one of the oldest and largest in the country. By putting our experience to work, we offer the best possible treatment outcomes.

Our leukemia clinicians and researchers have dedicated their clinical and research careers to improving our ability to diagnose and treat patients with leukemia.

It is this relentless pursuit for the very best clinical outcome and quality of life that drives Penn’s Leukemia Program.

Penn’s program is distinguished in a number of ways:

  • The Leukemia Program began in 1975 and since 1999 has been under the direction of Selina Luger, MD.
  • The Leukemia Program is the largest program in the tri-state area. Over 320 new patients are seen each year.
  • Penn has one of the largest and most experienced teams of leukemia specialists who have been working together for years.
  • When inpatient treatment is required, patients are cared for in a dedicated inpatient oncology unit staffed by physicians, nurses and pharmacists with expertise in these diseases.
  • The Program offers patients cutting edge therapy options including innovative in-house clinical trials as well as national multi-institutional trials such as Eastern Cooperative Oncology Group (ECOG) trials.
  • Penn pioneered the clinical trial using autologous transplant for acute myeloid leukemia (AML). This led to national trials which resulted in the use of autologous transplant as the standard of care for AML.
  • Dr. Luger is the principal investigator of a number of ECOG trials and the program is one of most successful participants in these trials.
  • Penn has one of the few Hematologic Malignancy (leukemia, lymphoma and myeloma) Research Programs in the country that is approved and funded by the National Cancer Institute.
  • A number of our junior faculty were recently awarded Leukemia and Lymphoma Society career development awards designed to foster the next generation of leaders in this field.
  • Our clinicians and investigators are active throughout the region in providing educational events for patients and health care providers.
  • Our faculty also serve as medical advisors for area outreach organizations, such as the Multiple Myeloma Networking Group and the Leukemia and Lymphoma Society.
  • Our clinicians have received numerous awards for their outstanding patient support activities.